Ex-Takeda execs bemoan reign of 'foreigners'

Takeda, Japan's largest drugmaker, has gone through a series of reorganizations in its efforts to take a bigger share of the global market, a process that has included recruiting leadership outside of its native country. That's not sitting very well with some former executives. CEO Yasuchika Hasegawa has led the charge for globalization at the company, installing French national Christophe Weber to serve as chief operating officer and, likely, be his successor. In response, 110 former execs and shareholders penned a chiding letter to Takeda, telling the Financial Times that the "company's globalization is a wrong globalization. It should be globalized as a Japanese company. Three main executive positions, finance, HR and purchase, are taken by foreigners. We cannot accept it." More

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.